HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paracetamol regulation findings

This article was originally published in The Tan Sheet

Executive Summary

Researchers found little evidence to support a hypothesis that regulations limiting paracetamol (acetaminophen) package sizes resulted in fewer poisoning deaths. Findings from an observational study by Oliver W. Morgan, Department of Primary Care and Social Medicine, Imperial College, London, et al., published in the April PLOS Medicine contradict a 2004 British Medical Journal study. The BMJ study found U.K. legislation limiting the number of acetaminophen and aspirin tablets sold in retail transactions reduced the number of overdose deaths (1"The Tan Sheet" Nov. 8, 2004, p. 9). Morgan et al. say decreased paracetamol-poisoning mortality coincided with the regulation. However, fatal poisonings involving aspirin and antidepressants also dropped. "This raises the question whether the decline in paracetamol deaths was due to the regulations or was part of a wider trend," they say...

You may also be interested in...



Acetaminophen-Related Overdose Deaths Down In UK Due To Law – BMJ

Legislation in the UK limiting the package sizes for acetaminophen and aspirin has reduced the number of deaths from overdose since its enactment in 1998, a study in the Oct. 29 British Medical Journal says

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel